Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JOINTSTEM
- Development stage
- Phase 3
- Lead developer
- NatureCell
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
JOINTSTEM is an autologous adipose-derived mesenchymal stem cell (MSC) therapy developed by Nature Cell and R Bio for the treatment of knee osteoarthritis. The therapy involves extracting a patient's own adipose tissue, isolating and expanding the mesenchymal stem cells in vitro, and then administering them back into the patient's knee joint via a single intra-articular injection. Once in the joint, these cells are thought to promote cartilage regeneration through the secretion of various growth factors and cytokines (paracrine effect), while also exerting anti-inflammatory and immunomodulatory effects to reduce pain and improve joint function. JOINTSTEM has completed Phase 3 clinical trials in South Korea and has been investigated in Phase 2 trials in the United States, representing a significant advancement in regenerative medicine for degenerative joint diseases.
- Brand names
- JOINTSTEM
- Other names
- autologous adipose-derived mesenchymal stem cellsAdipose-derived stem cells
Beyond the preview
Go deeper on JOINTSTEM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JOINTSTEM.